Nivolumab plus chemotherapy for advanced gastric cancer and oesophageal adenocarcinoma
- PMID: 34158606
- DOI: 10.1038/s41575-021-00484-8
Nivolumab plus chemotherapy for advanced gastric cancer and oesophageal adenocarcinoma
References
Original article
-
- Janjigian, Y. Y. et al. First-line nivolumab plus chemotherapy versus chemotherapy alone for advanced gastric, gastro-oesophageal junction, and oesophageal adenocarcinoma (CheckMate 649): a randomised, open-label, phase 3 trial. Lancet https://doi.org/10.1016/S0140-6736(21)00797-2 (2021) - DOI - PubMed